Merus N.V. (MRUS) Soars 5.5%: Is Further Upside Left in the Stock?Zacks Investment Research • 10/17/23
Merus Announces Abstracts Accepted for Presentation at the ESMO Asia Congress 2023GlobeNewsWire • 10/06/23
Merus Announces Financial Results for the Second Quarter 2023 and Provides Business UpdateGlobeNewsWire • 08/07/23
Merus Announces Two Clinical Abstracts on Zenocutuzumab (Zeno) in NRG1-fusion (NRG1+) non-small cell lung cancer (NSCLC) and Pancreatic Cancer (PDAC) Selected for Presentation at the ESMO Congress 2023GlobeNewsWire • 07/28/23
Zenocutuzumab (Zeno) granted second Breakthrough Therapy Designation by the U.S. Food & Drug AdministrationGlobeNewsWire • 07/05/23
Zenocutuzumab (Zeno) granted Breakthrough Therapy Designation by the U.S. Food & Drug Administration for the treatment of NRG1+ pancreatic cancerGlobeNewsWire • 06/29/23
Merus Appoints Life Sciences Strategic and Financial Industry Veteran Greg Perry as Chief Financial OfficerGlobeNewsWire • 06/15/23
Wall Street Analysts Believe Merus N.V. (MRUS) Could Rally 114.58%: Here's is How to TradeZacks Investment Research • 05/10/23
Merus Announces Financial Results for the First Quarter 2023 and Provides Business UpdateGlobeNewsWire • 05/04/23
Analysts Estimate Merus N.V. (MRUS) to Report a Decline in Earnings: What to Look Out forZacks Investment Research • 05/01/23
Merus' Petosemtamab Interim Data Demonstrates Clinically Meaningful Activity in Previously Treated Head and Neck Squamous Cell Carcinoma (HNSCC)GlobeNewsWire • 04/17/23
Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2023 and Provides a Program and Regulatory UpdateGlobeNewsWire • 04/14/23
Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR Annual Meeting 2023GlobeNewsWire • 04/14/23
Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2023GlobeNewsWire • 03/14/23
Merus Announces Petosemtamab in Previously Treated Head and Neck Squamous Cell Carcinoma Abstract Selected for Plenary Session Oral Presentation at the AACR Annual Meeting 2023GlobeNewsWire • 03/14/23
Merus Announces Financial Results for the Fourth Quarter and Full Year 2022 and Provides Business UpdateGlobeNewsWire • 02/28/23